We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Blog

Measuring Millions of Protein–Protein Interactions Simultaneously
Blog

We recently had the pleasure of speaking with David Younger, PhD., Co-founder and CEO of A-Alpha Bio, to learn more about AlphaSeq – a platform designed to measure millions of protein–protein interactions simultaneously.

Read More

Cell Conversions Transformed From Black Box Guesswork to Systematic Discovery
Blog

Predicting the reprogramming factors necessary to induce cell conversion has largely relied on trial and error, revealing the need for a more systematic approach. To learn about Mogrify's approach to achieving cell conversion through transdifferentiation, we interviewed Pierre-Louis Joffrin, Corporate Development Executive at Mogrify.

Read More

Exploring the Fourth Dimension of Proteome Analysis
Blog

Recent developments in MS technology have enabled a fourth dimension of analysis: ion mobility separation. The term "4D proteomics" has been created to describe analysis that incorporates all four dimensions. We interviewed two researchers at the forefront of the proteomics field to learn more about how 4D proteomics approaches are enhancing their research.


Read More

Clinical Proteomics and Computational Biochemistry With Professor Jürgen Cox
Blog

Technology Networks recently spoke with Professor Jürgen Cox to learn more about the computational software tools his laboratory are developing, and how 4D proteomics workflows enhance research in clinical proteomics.

Read More

Talking Clinical Proteomics With Dr Roman Fischer
Blog

Technology Networks spoke with Dr Roman Fischer to learn more about the challenges researchers face in the field of clinical proteomics, and how 4D proteomics workflows are enhancing his laboratory's work.

Read More

10 Things to Note About Manufacturing Viral Vectors
Blog

10 things to note about viral vector manufacturing, regarding the complexities and challenges, and the technology that will help drive cell and gene therapy forward. Here we share insights from Pall and Molmed representatives, who are leaders in the fields of bioprocessing and cell and gene therapy.

Read More

Harnessing the Power of Proteins To Unlock Cell and Gene Therapies
Blog

We recently spoke with Paul Wotton, Ph.D., CEO at Obsidian Therapeutics, to gain his insights on the genetically engineered cell-therapy research area, and to learn how Obsidian Therapeutics' cytoDRiVE platform can increases the specificity and safety of such therapies.

Read More

Developing Novel Therapies for the Treatment of Respiratory Diseases
Blog

We recently had the pleasure of speaking with Martin Gosling, Enterprise Therapeutics’ CSO and Professor of Molecular Pharmacology at the University of Sussex. Martin highlights the respiratory diseases Enterprise Therapeutics primarily focus on and the new disease modifying therapies they have in development.

Read More

First-of-its-Kind Cyclic IMS Promises Unlimited Experimental Opportunities
Blog

Ion mobility spectrometry (IMS) coupled to mass spectrometry (MS) has witnessed significant growth over the last two decades. To better understand IMS, the benefits this technology provides, and exactly what Waters' new SELECT SERIES CyclicTM IMS offers, we spoke to Emma Marsden-Edwards.

Read More

Targeting Tau Pathology to Slow Alzheimer’s Disease Progression
Blog

To learn more about AC Immune's series of compounds designed to target tau aggregation, we recently spoke with Prof. Andrea Pfeifer, the company's Chief Executive Officer.

Read More